Overview

Open-label Trial in Parkinson's Disease (PD)

Status:
Recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.

Phase:

Phase 3

Details

Lead Sponsor:

Cerevel Therapeutics, LLC